As Chief Commercial Officer (CCO) of AnaBios, Dr. Chris Mathes provides leadership in business development activities and contributes to the strategic direction of the company.
Previously, Mathes acted as the CCO of the early drug discovery company, Icagen. Prior to Icagen, Dr. Mathes led North American business development efforts for Discovery services at Charles River Laboratories. Dr. Mathes was CCO at ChanTest (acquired by Charles River in 2014), a market leader in ion channel drug discovery and associated in vitro safety testing. Prior to ChanTest, he established and managed all aspects of the U.S. subsidiary of Sophion Bioscience A/S (Denmark) as Vice President & General Manager.
Mathes has over 25 years of experience in the ion channel field and contributed to the early development and marketing strategy of automated patch clamp systems. He earned a B.S. in Biology from Stanford University (with departmental honors). He received his Ph.D. in Neuroscience from the University of California, Los Angeles in 1995. In 2009, Mathes earned an Executive M.B.A. degree from Rutgers University. He established Candidate Biopharma Advisors in January 2018.